With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an expansion and putting more color on its filing plans with the FDA. In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results